Kardigan
NASDAQ · KARD·South San Francisco, CA·Small-cap·Phase 2
Public precision cardiovascular therapeutics company founded by MyoKardia veterans. Its clinical pipeline targets genetic dilated cardiomyopathy, calcific aortic valve stenosis, and acute severe hypertension with danicamtiv, ataciguat, and tonlamarsen.
Decks (2)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Kardigan Corporate Presentation | Corporate overview | September 1, 2026 | 35 | Source |
| Kardigan website | Website | May 6, 2026 | 4 | Website |